iga glomerulonephritis

Summary

Summary: A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.

Top Publications

  1. Kawasaki Y, Hosoya M, Suzuki J, Onishi N, Takahashi A, Isome M, et al. Efficacy of multidrug therapy combined with mizoribine in children with diffuse IgA nephropathy in comparison with multidrug therapy without mizoribine and with methylprednisolone pulse therapy. Am J Nephrol. 2004;24:576-81 pubmed
  2. Beerman I, Novak J, Wyatt R, Julian B, Gharavi A. The genetics of IgA nephropathy. Nat Clin Pract Nephrol. 2007;3:325-38 pubmed
    ..We discuss recent developments in analytic tools that should enable genetic studies of sporadic forms of disease by the genome-wide association approach...
  3. Malycha F, Eggermann T, Hristov M, Schena F, Mertens P, Zerres K, et al. No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients. Nephrol Dial Transplant. 2009;24:321-4 pubmed publisher
    ..Mosaic mutations of cosmc have been shown to result in autoimmune disease. We hypothesized that cosmc mutations might contribute to the altered IgA1 galactosylation in IgAN patients...
  4. Bantis C, Heering P, Aker S, Kuhr N, Grabensee B, Ivens K. Influence of cytokine gene polymorphisms on IgA nephropathy. Ren Fail. 2008;30:135-40 pubmed publisher
    ..Conclusion. Our results suggest that TGF-beta1 gene Arg(25)-->Pro, TNFalpha gene G-308A, and IL-6 gene G-174C polymorphisms are not risk factors or markers of progression in Caucasian patients with IgA nephropathy...
  5. Haas M, Rahman M, Cohn R, Fathallah Shaykh S, Ansari A, Bartosh S. IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant. 2008;23:2537-45 pubmed publisher
    ..Some of this variability may be related to differences in histologic severity of cohorts of patients diagnosed as children versus adults...
  6. Moranne O, Watier L, Rossert J, Stengel B. Primary glomerulonephritis: an update on renal survival and determinants of progression. QJM. 2008;101:215-24 pubmed publisher
    ..Few epidemiological studies have investigated the long-term outcome of primary glomerulonephritis (GN) and its determinants in the decade since angiotensin-converting enzyme inhibitors entered widespread use...
  7. Paterson A, Liu X, Wang K, Magistroni R, Song X, Kappel J, et al. Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol. 2007;18:2408-15 pubmed
    ..Taken together, these data provide strong evidence for a novel disease susceptibility locus for familial IgAN...
  8. Hogg R, Fitzgibbons L, Atkins C, Nardelli N, Bay R. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. Clin J Am Soc Nephrol. 2006;1:1167-72 pubmed
    ..38, P < 0.001). It is concluded from these data that the effect of Omacor on proteinuria in patients with IgAN is dosage dependent and is associated with a dosage-dependent effect of Omacor on plasma phospholipid EPA and DHA levels...
  9. Giannakakis K, Feriozzi S, Perez M, Faraggiana T, Muda A. Aberrantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy. J Am Soc Nephrol. 2007;18:3139-46 pubmed

More Information

Publications62

  1. Courtney A, McNamee P, Heggarty S, Middleton D, Maxwell A. Association of functional haem oxygenase-1 gene promoter polymorphism with polycystic kidney disease and IgA nephropathy. Nephrol Dial Transplant. 2008;23:608-11 pubmed
    ..We report the first assessment of the role of this HO-1 gene promoter polymorphism in chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy (IgAN)...
  2. Ikezumi Y, Suzuki T, Karasawa T, Kawachi H, Nikolic Paterson D, Uchiyama M. Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy. Pediatr Nephrol. 2008;23:645-50 pubmed
    ..The ability of Miz to reduce the number of activated macrophages may be an important mechanism by which this drug ameliorated renal disease in these patients...
  3. Matsukura H, Miya K, Arai M, Miyawaki T, Inaba S. Minimal change variants with mesangial IgA deposits. Clin Nephrol. 2007;68:337-8 pubmed
  4. Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880-8 pubmed
  5. Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1:511-7 pubmed
    ..8 to 14.6 +/- 15.2% in the prednisolone group (P = 0.0003). The frequency of adverse effects was similar in the two groups. It is concluded that combination treatment may be better for severe IgAN than treatment with prednisolone alone...
  6. Kaartinen K, Syrjanen J, Porsti I, Hurme M, Harmoinen A, Pasternack A, et al. Inflammatory markers and the progression of IgA glomerulonephritis. Nephrol Dial Transplant. 2008;23:1285-90 pubmed
    b>IgA glomerulonephritis (IgAGN) composes a variable prognosis with 15-40% of the patients eventually progressing to end-stage renal failure...
  7. Philibert D, Cattran D, Cook T. Clinicopathologic correlation in IgA nephropathy. Semin Nephrol. 2008;28:10-7 pubmed publisher
    ..These include the clinical scenarios of modest proteinuria, acute kidney injury, and the nephrotic syndrome...
  8. Yoshikawa N, Nakanishi K, Ishikura K, Hataya H, Iijima K, Honda M. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study. Pediatr Nephrol. 2008;23:757-63 pubmed publisher
    ..No patients required a change of treatment. In conclusion, the efficacy and safety of the mizoribine combination seems to be acceptable for treating children with severe IgA-N...
  9. Pisani A, Sessa A, Sabbatini M, Andreucci M, Fusco C, Balletta M, et al. [Fabry nephropathy in a female with superposed IgA glomerulonephritis]. G Ital Nefrol. 2005;22:385-9 pubmed
    ..However, female carriers can accumulate GSL in their renal cells despite the absence of clinically evident kidney disease...
  10. Bisceglia L, Cerullo G, Forabosco P, Torres D, Scolari F, Di Perna M, et al. Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet. 2006;79:1130-4 pubmed
    ..Although we identified new candidate regions, replication studies are required to confirm the genetic contribution to familial IgAN...
  11. Goumenos D, Brown C. Therapeutic approach of patients with IgA nephropathy. Ren Fail. 2004;26:171-7 pubmed
    ..Combinations of corticosteroids and cytotoxic drugs are saved for patients with IgA nephropathy and a rapidly progressive course...
  12. Kawasaki Y, Suzuki J, Nozawa R, Sakai N, Tannji M, Isome M, et al. FB21, a monoclonal antibody that reacts with a sialic-acid-dependent carbohydrate epitope, is a marker for glomerular endothelial cell injury. Am J Kidney Dis. 2004;44:239-49 pubmed
    ..We evaluated FB21 staining in fetal kidneys and kidneys of children and adults with normal kidneys and glomerulonephritis and investigated whether FB21 can be used as a marker for endothelial cell injury...
  13. García Camín R, Cabezas A, Calero F, Ballarin J. [Steroid-responsive nephrotic syndrome in IgA nephropathy]. Nefrologia. 2004;24 Suppl 3:68-71 pubmed
    ..6 g/d and C. creat. 59 ml/min...
  14. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K, et al. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int. 2004;46:576-9 pubmed
    ..However, histologic alterations following the therapy have not been reported...
  15. Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol. 2005;64:35-40 pubmed
  16. Li P, Leung C, Chow K, Cheng Y, Fung S, Mak S, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751-60 pubmed
    ..We performed a double-blind, randomized, placebo-controlled, multicenter study on the ARB valsartan in the treatment of patients with immunoglobulin A (IgA) nephropathy...
  17. Westhoff T, Waldherr R, Loddenkemper C, Ries W, Zidek W, van der Giet M. Mesangial IgA deposition in minimal change nephrotic syndrome: coincidence of different entities or variant of minimal change disease?. Clin Nephrol. 2006;65:203-7 pubmed
    ..We describe 2 cases of MCA with analogue histological findings but relevant differences in clinical presentation, and we discuss the clinical implications of mesangial IgA deposition in minimal change nephrotic syndrome...
  18. Li G, Zhang H, Lv J, Shen Y, Wang H. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int. 2007;71:448-53 pubmed
    ..0298, P=1.258 x 10(-5), OR=3.03) were significantly higher in patients than in controls. The present study suggested that the polymorphisms of C1GALT1 gene were associated with the genetic susceptibility to IgAN in Chinese population...
  19. Kobori H, Katsurada A, Ozawa Y, Satou R, Miyata K, Hase N, et al. Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. Biochem Biophys Res Commun. 2007;358:156-63 pubmed
  20. Samuels J, Strippoli G, Craig J, Schena F, Molony D. Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton). 2004;9:177-85 pubmed
    ..43). Although the optimal management of patients with IgA nephropathy remains uncertain because of limitations with the existing published data, immunosuppressive agents are a promising strategy and should be investigated further...
  21. Alexopoulos E. Treatment of primary IgA nephropathy. Kidney Int. 2004;65:341-55 pubmed
  22. Batra A, Smith A, Feehally J, Barratt J. T-cell homing receptor expression in IgA nephropathy. Nephrol Dial Transplant. 2007;22:2540-8 pubmed
    ..We investigated the HR expression of T-cell subsets in IgAN, healthy adults and membranous nephropathy (MN)...
  23. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi G, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157-63 pubmed
    ..The histologic picture and proteinuria during early and late follow-up improve the prediction of outcome, but considerable variability remains outside the model...
  24. Coppo R, D Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18:503-12 pubmed
    ..Neither had prognostic value the finding of crescents involving up to 75% of glomeruli...
  25. Qin W, Zhou Q, Yang L, Li Z, Su B, Luo H, et al. Peripheral B lymphocyte beta1,3-galactosyltransferase and chaperone expression in immunoglobulin A nephropathy. J Intern Med. 2005;258:467-77 pubmed
    ..The current study was carried out to elucidate the expression level of beta1,3GT (C1GALT1) and its chaperone (Cosmc) in IgAN, and their relationships with clinical features as well as IgA glycosylation level...
  26. Simon P, Ramee M, Boulahrouz R, Stanescu C, Charasse C, Ang K, et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int. 2004;66:905-8 pubmed
    ..The stability of annual incidence according to period and age, which is demonstrated for the first time during the last period, provides a new evidence of a role for genetic factors in the pathogenesis of IgAN...
  27. Descamps Latscha B, Witko Sarsat V, Nguyen Khoa T, Nguyen A, Gausson V, Mothu N, et al. Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers. Kidney Int. 2004;66:1606-12 pubmed
  28. Lee H, Lee M, Lee S, Lee S, Lee E, Lee E, et al. Histological grading of IgA nephropathy predicting renal outcome: revisiting H. S. Lee's glomerular grading system. Nephrol Dial Transplant. 2005;20:342-8 pubmed
    ..The glomerular grading system is useful to compare biopsy specimens and to predict the natural course of disease in IgA nephropathy (IgAN), although no grading system can be perfect...
  29. Chan L, Leung J, Tang S, Choy C, Lai K. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol. 2005;16:2306-17 pubmed
    ..The data suggest that appropriate control of Ang II receptor activities in PTEC may ameliorate tubulointerstitial injury in IgAN...
  30. Lim C, Kim Y, Chae D, Ahn C, Han J, Kim S, et al. Association of C-509T and T869C polymorphisms of transforming growth factor-beta1 gene with susceptibility to and progression of IgA nephropathy. Clin Nephrol. 2005;63:61-7 pubmed
    ..The transcriptional activity of the gene for TGF-beta1 and the plasma levels of TGF-beta1 protein are associated with C-509T polymorphism at the promoter region, and with T869C (Leu 10Pro) polymorphism at codon 10, of the TGF-beta1 gene...
  31. Kawasaki Y, Suzuki J, Sakai N, Etoh S, Murai H, Nozawa R, et al. Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy. Am J Nephrol. 2004;24:147-53 pubmed
    ..There have been only a few studies concerning oral prednisolone and mizoribine therapy for diffuse IgA nephritis (IgAN). We evaluated the efficacy of prednisolone and mizoribine therapy for diffuse IgAN...
  32. Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int. 2004;65:1544-7 pubmed
    ..Drugs can be targeted to the effects enhanced by aberrantly glycosylated IgA1 on mesangial cells. Recent data suggest that aberrant IgA1 glycosylation may modulate clinical expression and progression of IgAN...
  33. Barratt J, Feehally J, Smith A. Pathogenesis of IgA nephropathy. Semin Nephrol. 2004;24:197-217 pubmed
    ..These new pathogenic insights have not yet led to new therapeutic opportunities...
  34. Sato F, Narita I, Goto S, Kondo D, Saito N, Ajiro J, et al. Transforming growth factor-beta1 gene polymorphism modifies the histological and clinical manifestations in Japanese patients with IgA nephropathy. Tissue Antigens. 2004;64:35-42 pubmed
    ..These results suggest that TGF-beta1 gene polymorphisms are specifically associated with heavy proteinuria and mesangial cell proliferation in Japanese patients with IgAN, although they do not confer susceptibility to this disease...
  35. Lai K, Chan L, Tang S, Tsang A, Li F, Lam M, et al. Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1. Kidney Int. 2004;66:1403-16 pubmed
    ..Preliminary studies showed a reduced glomerular gene expression of angiotensin II subtype 1 receptor (AT1R), suggesting a regulatory response to high intrarenal angiotensin II (Ang II) concentration in IgAN...
  36. Gherghiceanu M, Penescu M, Mandache E. The predictive value of peritubular capillaries C3d deposition in IgA glomerulonephritis. J Cell Mol Med. 2005;9:143-52 pubmed
    The IgA glomerulonephritis (IgAGN) is one of the most common primary glomerulonephritis and has a variable and difficult to predict evolution toward the end-stage nephrosclerosis...
  37. Julian B, Wyatt R, Matousovic K, Moldoveanu Z, Mestecky J, Novak J. IgA nephropathy: a clinical overview. Contrib Nephrol. 2007;157:19-26 pubmed
    ..These or other related findings may provide the necessary tools to better classify phenotypes in multiplex pedigrees and to improve monitoring of disease progression or response to therapy...
  38. Izzi C, Ravani P, Torres D, Prati E, Viola B, Guerini S, et al. IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis. 2006;47:761-9 pubmed
    ..Familial and sporadic cases are recognized, and a locus associated with the familial form of the disease was mapped to chromosome 6. Recent data suggest the familial IgA nephropathy form may have a poorer outcome than the sporadic form...
  39. Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006;69:1934-8 pubmed
    ..At present, there is insufficient evidence for the additional use of immunosuppressive agents, antiplatelet agents, or anticoagulants...
  40. Nozawa R, Suzuki J, Takahashi A, Isome M, Kawasaki Y, Suzuki S, et al. Clinicopathological features and the prognosis of IgA nephropathy in Japanese children on long-term observation. Clin Nephrol. 2005;64:171-9 pubmed
    ..Clinicopathological features were investigated to clarify the ultimate prognosis and prognostic indicators for patients with IgA nephropathy in Japanese children...
  41. Coppo R, Amore A, Peruzzi L, Mancuso D, Camilla R. Angiotensin antagonists and fish oil for treating IgA nephropathy. Contrib Nephrol. 2007;157:27-36 pubmed
    ..In conclusion, ACE-I and ARB have a definite role in treating IgAN, particularly the hypertensive and proteinuric forms. These patients should be treated to target BP to <130/70 mm Hg and proteinuria <0.5 g/day...
  42. Locatelli F, Vecchio L, Pozzi C. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors. Nat Clin Pract Nephrol. 2006;2:24-31 pubmed
    b>IgA glomerulonephritis accounts for 25-50% of renal biopsy diagnoses. About 25-50% of patients progress to end-stage renal disease within 20 years of diagnosis...
  43. Kaartinen K, Syrjanen J, Porsti I, Harmoinen A, Pasternack A, Huhtala H, et al. Insulin resistance and the progression of IgA glomerulonephritis. Nephrol Dial Transplant. 2007;22:778-83 pubmed
    b>IgA glomerulonephritis (IgAGN) has a highly variable prognosis with 15-40% of patients progressing to end-stage renal disease. Hypertension, proteinuria and renal insufficiency are risk factors associated with poor prognosis...
  44. Xia Y, Huang S, Li X, Yang N, Huang J, Xue C, et al. A family-based association study of megsin A23167G polymorphism with susceptibility and progression of IgA nephropathy in a Chinese population. Clin Nephrol. 2006;65:153-9 pubmed
    ..To investigate the association of megsin A23167G polymorphism with susceptibility and progression of IgA nephropathy in Chinese population...
  45. Moura I, Arcos Fajardo M, Sadaka C, Leroy V, Benhamou M, Novak J, et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol. 2004;15:622-34 pubmed
    ..These results indicate that aberrant glycosylation of IgA1 as well as immune complex formation constitute essential factors favoring mesangial TfR-IgA1 interaction as initial steps in IgAN pathogenesis...
  46. Wang Y, Zhao M, Zhang Y, Li X, Wang H. Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells. Clin Exp Immunol. 2004;136:168-75 pubmed
    ..This suggests that direct interaction between IgA1 and HMC and subsequential pathophysiological responses may play an important role in the pathogenesis for IgAN...
  47. Chan J, Trachtman H. Modulating the progression in IgA nephropathy. Nephron Clin Pract. 2006;104:c61-8 pubmed
    ..Therapeutic options are discussed including angiotensin-converting enzyme blockade, steroids, cytotoxics, tonsillectomy, fish oil, vitamin E, singly or in combination, in order to modulate the rate of progression...
  48. Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006;21:2800-8 pubmed
    ..Although there are several prognostic indicators, it remains difficult to predict the renal outcome in individual patients...
  49. Carturan S, Roccatello D, Menegatti E, Di Simone D, Davit A, Piazza A, et al. Association between transforming growth factor beta1 gene polymorphisms and IgA nephropathy. J Nephrol. 2004;17:786-93 pubmed
    ..We investigated whether G-800A, C-509T and Leu10-->Pro polymorphisms in the TGF-beta1 gene could be involved in the development and progression of immunoglobulin A nephropathy (IgAN)...
  50. Xu L, Zhao M. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int. 2005;68:167-72 pubmed
    ..The aim of the current study is to investigate whether aberrantly glycosylated IgA1 was associated with pathologic phenotypes of IgAN...
  51. Miyake Ogawa C, Miyazaki M, Abe K, Harada T, Ozono Y, Sakai H, et al. Tissue-specific expression of renin-angiotensin system components in IgA nephropathy. Am J Nephrol. 2005;25:1-12 pubmed
  52. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005;16:2088-97 pubmed
  53. Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, et al. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy. Hypertens Res. 2004;27:963-70 pubmed
    ..This strategy apparently reduced mild-to-moderate proteinuria in patients with normotensive IgA nephropathy...